Alexion
121 Seaport Blvd Boston
Boston
MA
02210
United States
Tel: 475-230-2596
Website: http://www.alexion.com/
About Alexion
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for nearly 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Company Ownership: Public
Stock Symbol: AZN
Stock Exchange: Nasdaq
711 articles with Alexion
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
Neurimmune enters into a collaboration and license agreement with AstraZeneca to develop and commercialize NI006
1/7/2022
Neurimmune AG announced that it has entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca's Rare Disease group, to develop NI006, an investigational human monoclonal antibody specifically targeting misfolded transthyretin.
-
As the capabilities have been proven, AI is establishing a firm foothold in the key areas of R&D, drug development, clinical trials, and, to some extent, patient-facing products.
-
AstraZeneca’s Alexion plans to buy all remaining equity in Caelum Biosciences and pick up Caelum’s CAEL-101 in the process.
-
Apellis Pharmaceuticals reported topline results from its Phase III DERBY and OAKS clinical trials for geographic atrophy secondary to age-related macular degeneration.
-
The FoCus Phase III trial by Alexion and AstraZeneca showed that ALXN1840 demonstrated around three times greater copper mobilization from tissues than SoC treatments for Wilson disease.
-
The group said that the Phase III trial of Ultomiris (ravulizumab) lacked efficacy when it was used on adults diagnosed with amyotrophic lateral sclerosis.
-
Boston-based Alexion Pharmaceuticals announced positive topline data from its Phase III trial of Ultomiris (ravulizumab-cwvz) in adults with generalized myasthenia gravis.
-
Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)
7/15/2021
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced positive topline results from a Phase 3 study evaluating the safety and efficacy of ULTOMIRIS® (ravulizumab-cwvz) in adults with generalized myasthenia gravis (gMG).
-
Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021
6/11/2021
Exploratory biomarker analyses suggest possible cardiac disease improvements and renal response
-
Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)
6/7/2021
Alexion Announces FDA Approval of ULTOMIRIS ® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH).
-
June is turning out to be a busy month for PDUFA dates for the U.S. Food and Drug Administration. Here’s a look at this week’s dates.
-
The UK’s Competition and Markets Authority (CMA) will determine if the deal is anti-competitive.
-
Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021
5/12/2021
Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that two abstracts on CAEL-101, a potentially first-in-class amyloid fibril targeted therapy, have been accepted for e-poster presentation at the European Hematology Association (EHA) Congress 2021, taking place virtually from June 9 to 17, 2021
-
Alexion Announces Upcoming Data Presentations at the 26th European Hematology Association Virtual Congress
5/12/2021
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that five abstracts have been accepted for presentation at the 26th annual European Hematology Association (EHA) 2021 virtual Congress, taking place from June 9 through June 17, 2021.
-
The Series A rounds are the latest in a string of financing announcements made over the past few months.
-
Alexion Shareholders Approve Acquisition by AstraZeneca
5/11/2021
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its shareholders have voted to adopt and approve the previously announced agreement to be acquired by AstraZeneca at a special meeting of shareholders held today.
-
BioSpace takes an in-depth look at the Top 25 of Q1.
-
Alexion Reports First Quarter 2021 Results
4/30/2021
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the first quarter of 2021. Total revenues in the first quarter were $1,636.5 million, a 13 percent increase compared to the same period in 2020.
-
UPDATED Alexion to Report First Quarter 2021 Results on Friday, April 30, 2021
4/28/2021
Alexion Pharmaceuticals, Inc. announced that the Company will report its financial results for the first quarter ended March 31, 2021 before the US financial markets open on April 30, 2021, rather than on May 3, 2021 as previously announced.